Yasmin Post Marketing Surveillance
Information source: Bayer
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Contraception
Intervention: EE30/DRSP (Yasmin, BAY86-5131) (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer
Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Summary
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety
and efficacy in real practice.
Clinical Details
Official title: Yasmin Regulatory Post Marketing Surveillance
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Safety and efficacy in real practice
Secondary outcome: DemographyMedical History Administration period of Yasmin Patient's compliance Adverse Event / Serious AE collection
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Women who need oral contraceptive
Exclusion Criteria:
- Patient who belongs to contraindication listed on the product label.
Locations and Contacts
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Many Locations, Korea, Republic of; Recruiting
Additional Information
Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
Starting date: March 2008
Last updated: January 18, 2013
|
